Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
07:52
PSD, PNL, USR and UDMR leaders, in discussions with President Nicușor Dan on the topic of the Salary Law / Romania loses 770 million euros if it does not adopt the law
07:42
Kosovo withdraws the symbols of support for Ukraine after Zelensky's refusal to recognize its independence
07:26
The earthquake toll in Colombia has risen to at least 132 dead and 570 injured.
07:09
Chronicle - Superliga | The red-blues are paler than a newly promoted team
06:59
Oana Gheorghiu, message for politicians eight years after the protest on August 10: "The day will come when you will pay. Even if justice does not succeed, the people will send you exactly where you belong."
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
